Abstract
Introduction

1
Patients in Critical Care Units (CCU) are prescribed nearly twice as many medications as patients in 2 other non CCU settings 1 . This increases the risk of drug interactions and medication errors 1 . 3
Medications require constant review and alteration to treat the patients' rapidly changing clinical need 4 and levels of organ dysfunction. Critically ill patients have limited physical reserves and are more 5 likely to experience an adverse drug event than other patients 1 . 6
It has been widely recognised that a highly skilled multidisciplinary team, which includes clinical 7 pharmacists, is fundamental to provide optimal care for this vulnerable patient population [2] [3] [4] [5] [6] [7] . Studies 8 have shown that the involvement of a clinical pharmacist in the care of critically ill patients improves 9 medication safety, e.g through identification of medication errors, drug interactions and avoidance of 10 adverse events or through optimisation of medicines 2, [8] [9] [10] [11] . Improved patient outcomes for critically ill 11 patients as well as cost savings have been demonstrated in various therapeutic areas such as 12 antimicrobial therapy or sedation management 3, 12 . However, the scope of pharmacy services to the 13 CCU and the competence of the team members varies between CCUs both within the UK and 14 internationally [13] [14] [15] . 15
In our study, the pharmacy service to the active critical care site was previously provided by a senior 16 clinical (non-specialist) pharmacist who had not received formal training in Critical Care and had core 17 responsibilities to other clinical areas in the hospital. Following a service review, a specialist, 18 dedicated, critical care pharmacist (defined at the time [prior to the introduction of formal 19 assessments] as a senior pharmacist specializing in and with prior experience of caring for critically ill 20 patients), was recruited (AR). This provided the opportunity to formally explore the effect of 21 introducing a specialist critical care pharmacist to the identified critical care unit. The design of the 22 service evaluation also included two CCUs in the same geographical area with established specialist 23 critical care pharmacists as controls. We focused on the impact of expanding pharmacy resource to 24 the CCU from a non-specialist pharmacist with responsibilities elsewhere in the hospital to a 25 dedicated critical care pharmacist (AR). 26
The aim of this study was to evaluate the impact of a dedicated specialist critical care pharmacy 27 service on patient care compared to a non-specialist clinical pharmacist service incorporating chart 28
review. 29
Our objectives were to study:
Friday) over a 6 week period during April-June 2009 before the introduction of the specialist critical 23 care pharmacist at the active site. 24
Phase 2 was a repeated data collection period over 6 weeks in April-June 2010, after the specialist 25 critical care pharmacist had been established for 4 months. 26
Pharmacists make interventions to solve drug-related problems, i.e. circumstances that are related or 27 potentially related to drug therapy that would interfere with optimal patient care. 28
We collected self-reported data on pharmacist interventions in the three CCUs using a standardised 29 data collection form based on Allenet et al 16 . The form is available from the authors on request.
All pharmacists working on the 3 CCUs were trained in the use of the form by discussing common 1 example interventions and definitions for terms used were provided on the back of the form to allow 2 for consistent data collection amongst all pharmacists. The data collected were: 3
• The type of drug related problem leading to pharmacist interventions 4
• The drug(s) and drug classes involved 5
• Whether a medication error had occurred or the pharmacist intervention was to optimise 6 medication 7
• Whether the pharmacist intervention was proactive or in reaction to the request of another 8 health care professional 9
• Whether the pharmacist intervention was made while attending the consultant-led 10 multidisciplinary ward round 11
• Whether the pharmacist intervention was accepted by the medical team 12
The data collection form was adapted following a pilot prior to phase 1. In the original data collection 13 tool by Allenet et al 16 the drug related problem category "failure to receive drug" related to intravenous 14 incompatibilities and non-compliance. It was felt that intravenous compatibility issues were better 15 reflected in the category "drug interaction" and that patient non-compliance was irrelevant in a CCU. A 16 new category "supply failure", i.e. unavailability of a medicine e.g. due to drug shortages, was 17 introduced as the researchers perceived this to be a drug-related problem of increasing relevance in 18 CCU. Other categories remained unchanged from the original tool, which were: 19
• Non-conformity to guidelines/best practice or contra indication 20
• Untreated indication 21
• Subtherapeutic dose 22
• Supratherapeutic dose 23
• Drug without indication 24
• Drug interaction / intravenous compatibility 25
• Adverse drug reaction 26
• Administration related 27
• Drug monitoring 28
Pharmacists also self-reported additional clinical activities undertaken as part of their CCU pharmacist 29 role.
Data management and analysis 3 4
After data collection was complete, one researcher (RS), a specialist critical care pharmacist at one of 5 the comparator hospitals, reviewed the categorisation of all pharmacist interventions into medication 6 error-related or optimisation of medication to ensure consistency throughout the data set. A 7 medication error was defined as an error in the process of prescribing, dispensing, preparing, 8 administering, monitoring or providing medicine advice, regardless of whether harm had occurred 17 . 9 'Optimisations' were recommendations made to improve pharmacotherapy which did not involve an 10
error. 11
RS also assessed the potential risk of harm from intercepted medication errors and the impact of 12 optimisation on patient outcome. A 4-point rating scale (low, moderate, severe, death) was used for 13 medication errors, adapted from the National Patient Safety Agency 18 and work by Folli et al 19 . A 14 corresponding 4-point scale (low, moderate, high, life-saving) was developed for optimisation 15 interventions. In order to address validity a random sample of 10% of all pharmacist interventions 16
were also scored by a second pharmacist, who was a medication safety expert and had not been 17 involved in the data collection (YJ). Any differences were resolved through discussion, and the agreed 18 principles were applied to the whole data set by RS. 19
Pharmacist intervention data was standardised by calculating the mean daily rate of pharmacist 20 interventions per hospital per study phase. 21
For data analysis of drug-related problems the two categories of drug related problems 22 'subtherapeutic dose' and 'supratherapeutic dose' on the data collection form were combined into a 23
Differences between study phases within each CCU were tested with independent sample T-tests or 25
Chi-squared tests. 26
Data was analysed using PASW Statistics 18 (SPSS Inc, Aug 2009). 27 28
Results
Baseline differences between the Critical Care Units are outlined in Table 1 . 1 2
Activity data 3
Quarterly bed occupancy data at all 3 hospitals during both study phases showed that although the 4 level of pharmacy service did not change at the comparator sites, there was a significant increase in 5 patient bed days at both comparator sites in phase 2 (Comparator 1 +13%, Comparator 2 +18%, 6 p<0.005). The increase in number of bed days (+10%) at the active site did not reach statistically 7 significance (p=0.054). 8 9
The mean rate of pharmacist interventions per day doubled at the active site from 2.69 in phase 1 to 10 5.45 in phase 2 (p<0.0005). There was no significant change in daily mean intervention rate between 11 study phases at the comparator hospitals, despite an increase in patient activity (p>0.05). This 12 increase in overall pharmacist intervention rate at the active site was largely due to an increase in 13 proactive interventions by the specialist pharmacist (2.05 vs 4.89, p<0.0005). The mean rate of 14 reactive pharmacist interventions (interventions in response to another health professional's enquiry) 15 remained unchanged between study phases (0.64 vs 0.55, p>0.05). The specialist pharmacist at the 16 active site made most interventions (62.5%) while participating on the consultant-led multidisciplinary 17 ward round. There had been no participation in the ward round previously. Both comparator units 18 showed no statistically significant differences in mean rate of proactive pharmacist interventions 19 between study phases (p>0.05), while a decrease in the rate of reactive pharmacist interventions 20 reached statistical significance for comparator 1 (p<0.05). 21
At the active site, the specialist pharmacist identified significantly more medication errors than the 22 non-specialist pharmacist. At both comparator hospitals the mean rate of medication error 23 interventions did not change significantly between study phases (p>0.05). 24
There was a numerical but not statistically significant increase in the rate of optimisation interventions 25 after the introduction of the specialist pharmacist, while there was a decrease of this type of 26 pharmacist intervention at the comparator hospitals (p<0.05 for comparator 2). 27 Table 2 provides a summary of pharmacist intervention rates for the active and comparator sites. 28 Over 90% of interventions by pharmacists were accepted by the medical team during both study 1 periods across all critical care units. There was no difference in clinician acceptance between study 2 phases at any of the hospitals (p>0.05). 3 4
Additional Clinical Pharmacist Activities 5
Additional clinical activities carried out by the specialist critical care pharmacist in phase 2 and not 6 previously available to the CCU during phase 1, were participation in the consultant-led 7 multidisciplinary ward round, medicines reconciliation, pharmacist involvement in CCU therapy audit 8 and guidelines, staff education and financial reporting. These activities were also carried out by 9 pharmacists at comparator sites during both study phases. Additionally, comparator sites had 10 pharmacist prescribers and offered a critical care training programme for junior pharmacists, which 11
was not available at the active site. 12 13 14
Categories of drug-related problems that resulted in pharmacist intervention 15
Pharmacists intervened in a wide range of drug related problems (Figure 1) . Examples of these are 16 shown in Table 3 . The most common categories of drug related problems at the active site were 17 sub-or supratherapeutic dose resulting in changing doses of medicines, non-conformity to 18 guideline/best practice or contraindication and administration-related problems. Interventions in the 19 category conformity to guidelines/contraindications were mostly related to guideline conformity, a 20 much smaller number addressed contraindications. During phase 2 there was a significant increase in 21 pharmacist interventions related to starting treatment for untreated indications, i.e. the specialist 22 pharmacist identified where an additional treatment for the patient was required, making this the 23 second most common type of intervention during phase 2. There were also significantly more 24 pharmacist interventions to stop medicines that were no longer required (drug without indication) in 25 phase 2 (Figure 1) . 26
Across all three sites the most frequent pharmacist interventions made were changing drug doses 27 and ensuring guideline/best practice conformity). Fewer interventions were made by pharmacists in all 28 hospitals regarding drug interactions, adverse events and supply failures. There was no change in 29
proportions of drug related problems across study phases at comparator 2 (p>0.05), the only categoryThe drug classes with the most frequent pharmacist intervention were anti-infectives, cardiac 1 medicines, as well as medicines affecting the central nervous system and the gastrointestinal tract. 2 3
Impact of pharmacist interventions on patient safety and optimisation of therapy 4
The significance of pharmacist interventions to patient care was assessed by grading the impact of 5 optimisation interventions and the severity of potential harm prevented from medication errors (table 6 4). Examples of interventions and their impact are provided in Table 3 . 7
Across both study phases the majority of pharmacist interventions potentially prevented moderate 8 harm from drug errors or had a moderate impact on optimisation of medicines. Numerically, there was 9 an increase in high impact optimisation and severe error interventions in phase 2 at the active site, 10 although changes did not reach statistical significance. In contrast, at both comparator sites the 11 proportion of severe errors and high impact optimisation interventions was lower in phase 2 (p<0.001 12 for drug errors). Changes in proportions of different grades of optimisation interventions did not reach 13 statistically significance at any study site. 14 15 16
Discussion
17
The introduction of a specialist critical care pharmacist led to a greater number of pharmacist 18 interventions, and regular pharmacist attendance at the physician-led multidisciplinary ward round. pharmacist in our study also led to the detection and prevention of significantly more medicationerrors. Our study design did not include patient outcome data to quantify whether this translated into 1 fewer actual adverse drug events but if more errors are intercepted, one might expect less adverse 2 events to follow. Moyen et al 24 report a rate of 10% of medication errors resulting in an adverse drug 3 event. Therefore it can be extrapolated that the increased pharmacist intervention rate after the 4 introduction of the specialist pharmacist at the active site will have improved patient safety by 5 detecting and preventing a greater number of medication errors. 6
7
Although in general not all errors lead to adverse drug events, a NICE review 25 reported that treating 8 or managing potentially avoidable adverse drug reactions that occur during inpatient stays may 9 increase the length of stay in hospital by 3 days. As the bed stay costs of intensive care are high, the 10 specialist critical care pharmacist contribution may lead to an improved healthcare cost avoidance 11
and an improvement in the utilisation of the finite number of critical care beds. 12
13
In this study it was shown that, in addition to the prevention and detection of medication errors, critical 14 care pharmacists also frequently optimised drug therapy. There was a numerical but not statistical 15 increase in optimisation interventions at the active site. Medication optimisation aims to help patients 16 benefit the most from their medicines, and further studies could focus on this aspect of the critical 17 care pharmacist's role. 18
A national study that has yet to report has found many UK CCUs are operating with a pharmacy 19 contribution well below the national standards 26 , in terms of specialism and time available. Our study 20
throws light on what may be expected by investing in specialist critical care pharmacist provision over 21 and above cover by a generalist with other responsibilities. 22
23
Aside from the demonstrated impact on pharmacist intervention rates, critical care pharmacists in this 24 study provided a greater range of additional clinical activities than the generalist pharmacist. It is not 25 intended for these to be the focus of this study but addition roles which were developed medication 26 safety initiatives, expenditure reporting, educational provision, contribution to the local and national 27 pharmacy initiatives and conducting audit and research. 28
The introduction of a specialist pharmacist increased the number of pharmacist interventions; 1 however this did not appear to change the proportion of high, moderate or low impact interventions. 2
The majority of both medication error and optimisation interventions were rated as having moderate 3 impact, a finding in line with another multi-centre critical care pharmacy intervention study 11, . 4
The inherent difficulty in rating impact is that the potential patient outcome without pharmacist 5 intervention can only be estimated, as pharmacist interventions are usually preventative in nature. 6
This applies even more to optimisation interventions. 7
Another possible explanation may be our observation that pharmacist interventions classified as 8 potentially having the highest impact were not necessarily the most complex interventions but could in 9 fact be simple. An example of this could be identifying that a penicillin allergic patient was prescribed 10 penicillin, or correcting an obvious overdose error. This is within the knowledge and skills of a non-11 specialist pharmacist. However, the strengths of critical care specialist pharmacists lie in assessing 12 complex patients with complex medication regimens in a specialty with often limited evidence base to 13 support practice 27, 28 . It is recognised that a certain level of training and expertise is required in order to 14 fulfil this role to best effect 26 . Therefore, minimum recommended knowledge and skills for Critical 15
Care pharmacists to support training and assessment have been published 29 . 16
Both comparator CCUs offered a junior pharmacist training programme for wider workforce 17 development, while this was only implemented at the active site after the study. 18
Formal assessment and accreditation of critical care specialist pharmacist practice did not exist in the 19 UK when the study was undertaken, but has since been developed 26 . 20
was not possible to control for the influence of acuity of patient groups, experience, grade, speciality 23 and competency of prescribers on pharmacist interventions rates. 24
Attributing the observed changes to the introduction of the specialist pharmacist is supported by no 25 change in these parameters at the comparator hospitals over the same time period. It is possible that 26 patient cohorts during both study periods differed, which may affect the number and types of 27 pharmacist intervention. We sought to avoid seasonal changes by carrying out the data collection 28 during the same months in consecutive years. None of the hospitals underwent major service 29 changes during our study; however bed occupancy data showed higher patient activity at all studysites, though the 10% increase at the active site did not reach statistical significance. While higher 1 patient activity may be clinically relevant, it does not explain the disproportionately larger increase 2 (100%) in intervention rate at the active site. Furthermore the increase in patient activity at the 3 comparator sites did not result in a corresponding significant increase in pharmacist intervention rate. 4
This supports the suggestion that the increase in pharmacist intervention rate at the active site is due 5 to the introduction of the critical care pharmacist post. 6
From our pragmatic study it was not possible to distinguish whether the increase volume of 7 interventions at the active site were due to the introduction of a dedicated pharmacist with increased 8 time allocated to the CCU or to increased critical care specialist knowledge and experience that the 9 individual had, though both may contribute. There is published data showing increased intervention 10 rates when pharmacist responsibility changes from multiple units to a dedicated CCU service 21 , as 11 well as data showing an inverse correlation between intervention rate of critical care pharmacists and 12 patients reviewed 22 . 13 14 pharmacist resource to the Critical Care Unit to a level recommended nationally for critical care 18 service provision 4, 23 . Although a randomized controlled trial would ideally be required to confirm our 19 findings, this study supports the international evidence of the positive impact of critical care 20 pharmacists and importantly provides new insights into the additional benefit that can be expected 21 from developing the pharmacy provision from a non-specialist generalist pharmacist with other 22 responsibilities in the hospital to a dedicated CCU specialist pharmacist. The use of multicentre 23 control sites supports the validity of the observed differences and adds to the limited published 24 evidence specific to critical care pharmacy services outside the US. Tables   Table 1 -Baseline differences between Critical Care Units   Table 2 
